Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

Category : Dolor

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

Expert Rev Gastroenterol Hepatol. 2017 Feb 16;:1-9

Authors: Hasenoehrl C, Storr M, Schicho R

Abstract
INTRODUCTION: Fifty years after the discovery of Δ(9)-tetrahydrocannabinol (THC) as the psychoactive component of Cannabis, we are assessing the possibility of translating this herb into clinical treatment of inflammatory bowel diseases (IBDs). Here, a discussion on the problems associated with a potential treatment is given. From first surveys and small clinical studies in patients with IBD we have learned that Cannabis is frequently used to alleviate diarrhea, abdominal pain, and loss of appetite. Single ingredients from Cannabis, such as THC and cannabidiol, commonly described as cannabinoids, are responsible for these effects. Synthetic cannabinoid receptor agonists are also termed cannabinoids, some of which, like dronabinol and nabilone, are already available with a narcotic prescription. Areas covered: Recent data on the effects of Cannabis/cannabinoids in experimental models of IBD and in clinical trials with IBD patients have been reviewed using a PubMed database search. A short background on the endocannabinoid system is also provided. Expert commentary: Cannabinoids could be helpful for certain symptoms of IBD, but there is still a lack of clinical studies to prove efficacy, tolerability and safety of cannabinoid-based medication for IBD patients, leaving medical professionals without evidence and guidelines.

PMID: 28276820 [PubMed – as supplied by publisher]

Powered by WPeMatico

Commentarios

comments


Translate »